Anesthesia for Breast Cancer Surgery 

Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.

Breast cancer surgery encompasses a spectrum of procedures ranging from lumpectomy with sentinel lymph node biopsy to modified radical mastectomy with immediate breast reconstruction. Anesthesia management should be individualized based on the type of surgery and the extent of breast cancer, patient comorbidities, postoperative pain expectations, and the need for rapid recovery. Modern perioperative care emphasizes multimodal analgesia, opioid-sparing techniques, and enhanced recovery after surgery (ERAS) principles to optimize patient outcomes while minimizing postoperative nausea, pain, and hospital length of stay.

General anesthesia is the standard form of anesthesia for many breast cancer procedures. Intravenous induction with propofol, followed by maintenance with either volatile anesthetics or total intravenous anesthesia (TIVA), provides reliable surgical conditions. The choice between inhalational anesthesia and TIVA has been extensively studied because of concerns regarding potential effects on cancer recurrence. Although laboratory studies have suggested that volatile anesthetics and opioids might suppress immune function, large randomized clinical trials have not demonstrated clinically significant differences in cancer recurrence or overall survival based on anesthetic technique. Consequently, the selection of anesthetic maintenance should be guided by patient-specific factors, anticipated postoperative recovery, and provider preference rather than concerns regarding oncologic outcomes. 

Regional anesthesia has become especially useful for breast cancer surgery because it significantly improves postoperative analgesia and reduces perioperative opioid consumption. Traditional thoracic paravertebral block has long been the standard regional technique for unilateral breast surgery, providing excellent analgesia with lower rates of postoperative nausea and vomiting compared with opioid-based analgesia. However, ultrasound-guided fascial plane blocks have gained popularity because they are technically easier and carry a lower risk of complications such as pneumothorax. 

The pectoral nerve (PECS I and PECS II) blocks effectively anesthetize the lateral and anterior chest wall and are particularly useful for mastectomy and axillary procedures. The serratus anterior plane block provides analgesia to the lateral thoracic wall by targeting the lateral cutaneous branches of the intercostal nerves, while the erector spinae plane block offers broader thoracic analgesia through spread into the paravertebral space. Current evidence suggests that these ultrasound-guided blocks provide meaningful reductions in postoperative pain scores and opioid requirements, particularly when incorporated into multimodal analgesic protocols.

Multimodal analgesia forms the foundation of perioperative pain management for breast surgery. Preoperative acetaminophen and nonsteroidal anti-inflammatory drugs, when not contraindicated, reduce opioid requirements throughout the perioperative period. Intraoperative dexamethasone provides both antiemetic and analgesic benefits, while regional anesthesia further decreases opioid consumption. Small doses of intravenous ketamine or lidocaine infusions may be considered in selected patients with chronic pain, opioid tolerance, or anticipated severe postoperative pain. These strategies contribute to earlier ambulation, improved patient satisfaction, and reduced opioid-related adverse effects.

Postoperative nausea and vomiting (PONV) remain common following breast surgery because the patient population consists predominantly of women undergoing relatively short procedures, often with exposure to opioids. Risk reduction includes multimodal prophylaxis using dexamethasone, a 5-HT3 receptor antagonist such as ondansetron, adequate intravenous hydration, and minimizing perioperative opioid administration through regional anesthesia and non-opioid analgesics. Patients with multiple PONV risk factors may benefit from additional antiemetic agents consistent with current consensus guidelines.

Enhanced Recovery After Surgery (ERAS) pathways have increasingly been adopted across surgical specialties. Key elements include patient education, shortened fasting intervals, goal-directed fluid therapy, opioid-sparing analgesia, early oral intake, and prompt mobilization. These protocols have consistently demonstrated reductions in postoperative complications, improved patient satisfaction, and increased rates of same-day discharge without compromising safety.

In contemporary practice, anesthesia for breast cancer surgery integrates evidence-based multimodal analgesia, ultrasound-guided regional anesthesia, aggressive PONV prevention, and ERAS principles to optimize perioperative recovery. While ongoing research continues to explore potential interactions between anesthetic management and cancer biology, current evidence supports tailoring anesthetic techniques to maximize patient comfort, facilitate rapid recovery, and improve the overall surgical experience.

References 

1. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: A randomized controlled trial. Lancet. 2019;394(10211):1807-1815. 10.1016/S0140-6736(19)32313-X 

2. El-Boghdadly K, Wolmarans M, Stengel AD, et al. Regional anaesthesia for breast surgery: Systematic review and meta-analysis. Br J Anaesth. 2021;126(1):57-70. 10.1016/j.bpa.2019.03.003 

3. Kehlet H, Joshi GP. Enhanced recovery after surgery: Current controversies and future directions. Anesth Analg. 2018;126(6):2150-2157. 10.1213/ANE.0000000000002231 

4. Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg. 2020;131(2):411-448. 10.1213/ANE.0000000000004833 

5. Blondeel PN, Morris SF, Hall-Findlay EJ, Neligan PC, eds. Perioperative management of patients undergoing breast reconstruction. Plast Reconstr Surg. 2022;149(1):1e-14e. 10.1097/PRS.0000000000003242